1
|
Wang J, Wu J, Li Y, Wen J, Cai J, Tang T, Hu X, Xiang D. The Brief Analysis of Peptide-combined Nanoparticle: Nanomedicine's Unique Value. Curr Protein Pept Sci 2021; 21:334-343. [PMID: 32039679 DOI: 10.2174/1389203721666200210103841] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Revised: 08/20/2019] [Accepted: 09/25/2019] [Indexed: 12/21/2022]
Abstract
Therapeutic peptides (TPs) are biological macromolecules which can act as neurotransmitters, hormones, ion channel ligands and growth factors. Undoubtedly, TPs are crucial in modern medicine. But low bio-stability and some special adverse reactions reduce their places to the application. With the development of nanotechnology, nanoparticles (NPs) in pharmaceutical science gained much attention. They can encapsulate the TPs into their membrane or shell. Therefore, they can protect the TPs against degradation and then increase the bioavailability, which was thought to be the biggest advantage of them. Additionally, targeting was also studied to improve the effect of TPs. However, there were some drawbacks of nano TPs like low loading efficiency and difficulty to manufacture. Nowadays, lots of studies focused on improving effect of TPs by preparing nanoparticles. In this review, we presented a brief analysis of peptide-combined nanoparticles. Their advantages and disadvantages were listed in terms of mechanism. And several examples of applications were summarized.
Collapse
Affiliation(s)
- Jiemin Wang
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Junyong Wu
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Yongjiang Li
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Jing Wen
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Jiaxin Cai
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Tiantian Tang
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Xiongbin Hu
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| | - Daxiong Xiang
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.,Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.,Institute of Clinical Pharmacy, Central South University, Changsha, China
| |
Collapse
|
2
|
Lu C, Li X, Liang X, Zhang X, Yin T, Gou J, He H, Zhang Y, Tang X. Liver Targeting Albumin-Coated Silybin-Phospholipid Particles Prepared by Nab™ Technology for Improving Treatment Effect of Acute Liver Damage in Intravenous Administration. AAPS PharmSciTech 2019; 20:293. [PMID: 31432294 DOI: 10.1208/s12249-019-1504-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Accepted: 08/05/2019] [Indexed: 01/29/2023] Open
Abstract
In this study, a novel human serum albumin nanoparticle loading silybin-phospholipid complex (SLNPs) was developed for liver targeting after intravenous administration. The preparation of the drug delivery system consisted of two steps; initially, a silybin-phospholipid complex (SLC) was produced to improve the lipophilicity of SLB to then achieve enhanced encapsulation of SLB in albumin nanoparticles. FT-IR and XRD analysis confirmed the successful formation of SLC. The complex ratio of SLC in the first step was 99.6%. The encapsulation efficiency and drug loading of SLNPs in the second step were 96.2% and 5.6%, respectively. SLNPs were spherical and well-dispersed, with a zeta potential of approximately - 10 mV, and a mean particle size around 200 nm. An in vivo tissue distribution experiment and a pharmacodynamic experiment showed that, compared with SLB solution, SLNPs had an improved SLB accumulation in the liver. The hepatoprotective effect of SLNPs on CCl4-induced acute liver damage was evaluated. CCl4-damaged mice showed an increased enzymatic activity of ALT and AST; however, enzyme levels returned to near-normal levels in high-dose SLNP-treated mice. As SLNPs combine the enhanced oil solubility of SLC and the passive targeting of albumin nanoparticles, they possess great potential for the treatment of acute liver damage.
Collapse
|
3
|
van der Steen SC, Raavé R, Langerak S, van Houdt L, van Duijnhoven SM, van Lith SA, Massuger LF, Daamen WF, Leenders WP, van Kuppevelt TH. Targeting the extracellular matrix of ovarian cancer using functionalized, drug loaded lyophilisomes. Eur J Pharm Biopharm 2017; 113:229-239. [DOI: 10.1016/j.ejpb.2016.12.010] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Revised: 12/05/2016] [Accepted: 12/09/2016] [Indexed: 12/12/2022]
|